Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.35, $0.20 better than the analyst estimate of $0.15. Revenue for the quarter came in at $62.2 million versus the consensus estimate of $60.44 million.

Pacira ended the third quarter of 2015 with cash and cash equivalents, short-term investments and long-term investments (“cash”) of $164.4 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.